Bridges C G, Ahmed S P, Kang M S, Nash R J, Porter E A, Tyms A S
MRC Collaborative Centre, London, UK.
Glycobiology. 1995 Mar;5(2):249-53. doi: 10.1093/glycob/5.2.249.
Oral treatment of mice, cutaneously infected with herpes simplex virus type 1 (HSV-1) (strain SC16), with the alpha-glucosidase 1 inhibitor 6-O-butanoyl castanospermine (MDL 28,574) produced a significant delay in lesion development and reduced the amount of virus recovered from the brain. Virus load in the brains of mice, whose treatment started 2 days prior to infection, was reduced approximately 100-fold when compared to untreated controls. Treatment initiated at the time of infection, while less effective than pre-treatment, nevertheless reduced virus recovery from the brain by 10-fold. Consistent with its antiviral activity, orally administered MDL 28,574 was rapidly incorporated by brain tissue and mice fed with compound over extended periods maintained relatively high levels of drug at this site.
用α-葡萄糖苷酶1抑制剂6-O-丁酰栗精胺（MDL 28,574）对皮肤感染1型单纯疱疹病毒（HSV-1）（SC16株）的小鼠进行口服治疗，可显著延迟损伤发展，并减少从脑中回收的病毒量。在感染前2天开始治疗的小鼠脑中的病毒载量，与未治疗的对照组相比降低了约100倍。在感染时开始治疗，虽然不如预先治疗有效，但仍使从脑中回收的病毒减少了10倍。与其抗病毒活性一致，口服的MDL 28,574能迅速被脑组织摄取，长期喂食该化合物的小鼠在此部位维持相对较高的药物水平。
